Literature DB >> 28953572

Complications of Urethral Bulking Agents for Stress Urinary Incontinence: An Extensive Review Including Case Reports.

Allert M de Vries, Harpreet Wadhwa1, Jason Huang1, Fawzy Farag2, John P F A Heesakkers, Ervin Kocjancic1.   

Abstract

OBJECTIVES: Stress urinary incontinence in women is a common problem that significantly impacts quality of life. Periurethral injection of urethral bulking agents (UBAs) is a simple, noninvasive, and cost-effective treatment. However, complications associated with UBA are often underappreciated. Objective of this review was to get a complete overview of all published complications of UBA.
METHODS: An extensive search of the scientific literature was conducted to quantitatively summarize the complications and their treatments of 8 UBAs. A total of 117 articles (original articles and case reports) were included in the final analysis. Complication incidence, treatment incidence, and follow-up time were extracted when mentioned. Statistical analysis of complication incidence of each UBA was calculated if possible.
RESULTS: A total of 2095 complications in 6462 treated patients were reported in 79 studies. Sixty-seven (3%) were considered serious implying operative correction (Clavien grade III); of these, 46 (69%) required incision and drainage, and 21 (31%) required a more invasive procedure. In 38 case reports and small case series, 49 patients were treated for 110 complications. Of these 110 complications, 41 (37%) can be classified as Clavien grade III.
CONCLUSIONS: This extensive review shows that various UBAs have different complication rates, with certain UBAs being more prone to serious complications. Based on available publications, most UBAs have a good safety profile, with low complication rates. However, although the majority of UBA complications are transient and require no or noninvasive treatment, serious complications may require invasive intervention and treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28953572     DOI: 10.1097/SPV.0000000000000495

Source DB:  PubMed          Journal:  Female Pelvic Med Reconstr Surg        ISSN: 2151-8378            Impact factor:   2.091


  6 in total

1.  A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence.

Authors:  Ron J Jankowski; Le Mai Tu; Christopher Carlson; Magali Robert; Kevin Carlson; David Quinlan; Andreas Eisenhardt; Min Chen; Scott Snyder; Ryan Pruchnic; Michael Chancellor; Roger Dmochowski; Melissa R Kaufman; Lesley Carr
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

Review 2.  Urethral Pathology in Women.

Authors:  Erin Maetzold; Elizabeth B Takacs
Journal:  Curr Urol Rep       Date:  2022-09-17       Impact factor: 2.862

3.  Urethral bulking agent found in a urethral caruncle which did not respond to topical oestrogens: A case report.

Authors:  Christopher Savvas; George Araklitis; Chirag Shah; Dudley Robinson; Linda Cardozo
Journal:  Case Rep Womens Health       Date:  2020-10-27

4.  Patients' satisfaction and safety of bulk injection therapy Urolastic for treatment of stress urinary incontinence: A cross-sectional study.

Authors:  Fenne M Casteleijn; Claudia R Kowalik; Claudia Berends; Mija Blaganje; Mateja Lasić Pecev; Ellen van der Linden; Sandra E Zwolsman; Jan-Paul W R Roovers; Pieter Minnee
Journal:  Neurourol Urodyn       Date:  2020-06-11       Impact factor: 2.696

5.  Medical malpractice in stress urinary incontinence management: A 30-year legal database review.

Authors:  Niccola B Lynch; Linhan Xu; David Ambinder; Rena D Malik
Journal:  Curr Urol       Date:  2021-08-02

6.  Clinical presentation and treatment of Macroplastique® urethral exposures: a retrospective case series.

Authors:  Laura Ramirez-Caban; Maral Malekzadeh; David A Ossin; Eric A Hurtado
Journal:  Int Urogynecol J       Date:  2021-07-02       Impact factor: 2.894

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.